Breast Cancer
Balixafortide in combination with eribulin did not improve objective response rate compared to eribulin alone for the treatment of HER2-negative, locally recurrent or metastatic breast cancer, missing the coprimary end point of the FORTRESS study.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap
2
INBRX-106/Pembrolizumab Shows Efficacy in First-Line HNSCC
3
Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment
4
Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC
5